Clinical trials
Multiple Sclerosis (MS) - Relapsing-remitting clinical trials
Below are recruiting multiple sclerosis (ms) - relapsing-remitting clinical trials, each written for real people, not researchers. We’re tracking 233 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05713890Recruiting
Home VR training for right arm function in MS
This study tests whether doing a virtual-reality–based training program at home can improve movement and daily use of the right arm and hand in people with multiple sclerosis. It may help reduce hand limitations by practicing targeted movement skills using an easy remote setup.
Milan, MilanAges 18–65 - NCT05633875Recruiting
MRI study to better understand worsening in multiple sclerosis
This study uses detailed imaging (mostly MRI) to look for patterns that may explain why multiple sclerosis can worsen. It may help researchers understand the biology behind neurodegeneration and improve future care.
ParisAges 18 years+ - NCT05539729RecruitingPhase 1
Testing vancomycin for newly diagnosed multiple sclerosis
This Phase 1 study tests whether the antibiotic vancomycin can be given safely to people with newly diagnosed multiple sclerosis (or related early stages). It mainly focuses on safety and side effects, and whether the approach is feasible for this group.
New York, New YorkAges 18–50 - NCT05491031Recruiting
MRI scan study to predict disability changes in MS
This study uses MRI scans to predict how quickly disability may worsen in people with multiple sclerosis (MS). It may help doctors spot people at higher risk of progression earlier.
PoitiersAges 18 years+ - NCT05418010RecruitingPhase 2
Natalizumab treatment for early multiple sclerosis-like symptoms
This Phase 2 study tests natalizumab to treat people who have had a first episode of symptoms suggestive of multiple sclerosis. It aims to see whether the treatment can help after early “demyelination” changes are seen on brain MRI.
LondonAges 18–55 - NCT05344469Recruiting
Testing new MS medicines in people with active relapsing MS
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
Albstadt, Baden-WurttembergAges 18–100 - NCT05357781Recruiting
Test immunoglobulin treatment for fatigue in multiple sclerosis
This trial studies whether giving immunoglobulins (antibody medicines) can improve fatigue in people with multiple sclerosis (MS). It will enroll only people whose MS and fatigue are stable and meet specific blood/health criteria.
Bern, Canton of BernAges 18–65 - NCT05162638Enrolling by invitation
Immune study in MS and healthy adults using a special tube
This study compares immune (defense system) “profiles” between people with multiple sclerosis (MS) and healthy volunteers. It involves a thoracic duct cannulation procedure and several MRIs to see how immune cells behave and whether a specific immune pattern is different in MS.
Philadelphia, PennsylvaniaAges 18–40 - NCT05061953Recruiting
Eye-tracking test software study in adults with multiple sclerosis
This study checks how well new eye-tracking software can measure eye movements in people with multiple sclerosis. It may help researchers track changes in how the nervous system works using a simple camera-based eye test.
Montreal, QuebecAges 18 years+ - NCT05051618Recruiting
Exercise program for depression in people with multiple sclerosis
This trial studies whether a structured exercise program can help reduce symptoms of major depressive disorder in people who also have multiple sclerosis. You’ll complete questionnaires, wear an activity sensor, and do exercise testing while being assigned to the study program.
Chicago, IllinoisAges 18–64 - NCT04873492Recruiting
Study how genes and blood signals relate to MS outcomes
This study looks at genetic information and blood test signals to understand why some people with early MS develop a worse outcome. It may help doctors predict who is at higher risk and better understand disease mechanisms.
Nantes, Loire-AtlantiqueAges 18 years+ - NCT04798651Recruiting
Study immune blood and spinal fluid cells in multiple sclerosis
This study looks at different immune cells in blood and, sometimes, spinal fluid (CSF) to understand what’s driving multiple sclerosis (MS) or early MS-like symptoms. Your participation may help researchers better explain the disease and potentially improve how it’s diagnosed or treated.
BordeauxAges 18 years+ - NCT04819737Recruiting
MRI scan study to better detect spinal cord changes in MS
This study tests new MRI scan methods to more clearly find spinal cord lesions in people with multiple sclerosis (MS). It may help improve how MS spinal cord changes are seen on scans.
BaselAges 18 years+ - NCT04390009RecruitingEarly Phase 1
Whole-body PET scans in people with multiple sclerosis
This early study tests how whole-body PET-CT scans can be used in people with multiple sclerosis (and compares with healthy volunteers). It may help researchers understand what the scan can show in MS throughout the body.
Ladera Ranch, CaliforniaAges 25–55 - NCT04415372Enrolling by invitation
MRI brain scan study for white and gray matter in MS
This study uses detailed MRI scans to look at brain “white matter” and “gray matter” changes in people with multiple sclerosis (MS). It may help researchers better understand how MS affects the brain and relates to symptoms.
Madison, WisconsinAges 18–60 - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55 - NCT03783416RecruitingPhase 1
Ixazomib safety study for people with multiple sclerosis
This early-phase study tests how safe ixazomib is for people with multiple sclerosis (MS). It focuses on targeting certain immune cells in MS and checks whether the treatment can be given safely.
London, Greater LondonAges 18–65 - NCT03291756Enrolling by invitation
CorEvitas Multiple Sclerosis registry for people starting MS medicine
This registry collects health information from adults with multiple sclerosis (MS) when they start an MS medicine. It may help researchers better understand treatment patterns and outcomes in real-world care.
Waltham, MassachusettsAges 18 years+ - NCT03109288RecruitingPhase 1/Phase 2
Biomarker-guided combination treatment for residual multiple sclerosis activity
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
Bethesda, MarylandAges 18–120 - NCT03032601Enrolling by invitation
N-acetyl cysteine study for people with multiple sclerosis
This study tests whether N-acetyl cysteine (a supplement-like medicine) changes body and brain function in people with multiple sclerosis. It may help researchers understand how it affects brain chemistry and activity using special brain imaging.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02659956Recruiting
Study brain and eye changes on MRI in MS
This study looks at how multiple sclerosis (MS) affects MRI scans and other measurements in the brain, spinal cord, and eyes. It may help researchers better understand MS changes over time, using follow-up visits and, in the future, donated tissue after death.
Bethesda, MarylandAges 18–120 - NCT01353547Recruiting
Study genes and environment in multiple sclerosis risk
This study looks at how genes and life exposures may relate to developing multiple sclerosis (MS) or to MS itself. You may be invited if you have a specific connection to MS or certain past immune-related treatments.
Bethesda, MarylandAges 18 years+ - NCT00001248Recruiting
MRI Brain Imaging Study for Multiple Sclerosis
This research study uses MRI (magnetic resonance imaging)—a safe, non-invasive scanner—to take detailed pictures of your brain and understand how multiple sclerosis (MS) affects it over time. You may qualify whether you have MS or are a healthy volunteer for comparison.
Bethesda, MarylandAges 18–120 - NCT07759115Recruiting
Music program to improve thinking in people with multiple sclerosis
This study tests a music-based program to see if it can help improve thinking and memory in people with multiple sclerosis. It is a small feasibility study to see if the program is practical and helpful.
Austin, TexasAges 18–80
Hear when a new Multiple Sclerosis (MS) - Relapsing-remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple sclerosis (ms) - relapsing-remitting?
- Yes. Clin2 currently lists 233 recruiting multiple sclerosis (ms) - relapsing-remitting studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple sclerosis (ms) - relapsing-remitting trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple sclerosis (ms) - relapsing-remitting trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.